论文部分内容阅读
目的观察重组人5型腺病毒注射液胸腔灌注对肺癌恶性胸腔积液的临床治疗效果。方法 45例肺癌恶性胸腔积液患者随机分为观察组(23例)和对照组(22例),两组均应用微创置管胸腔闭式引流结合局部注药,观察组胸腔内局部灌注重组人5型腺病毒注射液,对照组局部灌注顺铂,观察胸腔积液控制情况、毒副反应。结果观察组胸液控制有效率为82.61%,完全缓解率47.83%;对照组有效率为40.91%,完全缓解率为18.18%,差异有统计学意义(P<0.05)。观察组和对照组均无严重不良反应。结论胸腔内局部灌注重组人5型腺病毒注射液在有效控制肺癌恶性胸腔积液方面明显优于顺铂,值得推广应用。
Objective To observe the clinical effect of recombinant human type 5 adenovirus injection in the treatment of malignant pleural effusion of lung cancer. Methods Forty-five patients with malignant pleural effusion from lung cancer were randomly divided into observation group (23 cases) and control group (22 cases). Both groups were performed minimally invasive thoracic closed drainage combined with local injection. The observation group intrathoracic local perfusion reorganization Human type 5 adenovirus injection and control group were infused with cisplatin, and the pleural effusion control and toxicity were observed. Results The effective rate of thoracic fluid control in the observation group was 82.61% and the complete remission rate was 47.83%. The effective rate in the control group was 40.91% and the complete remission rate was 18.18%. The difference was statistically significant (P<0.05). No serious adverse reactions were observed in the observation group and the control group. Conclusion Local injection of recombinant human adenovirus type 5 in the thoracic cavity is significantly superior to cisplatin in the control of malignant pleural effusion of lung cancer. It is worthy of popularization and application.